Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 21 от 154

Набира участници

Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial)

Blood Culture Contamination Infection

Blood cultures (BCs) are a blood test to look for an infection. Two problems with the sample collection are contamination by germs outside of the blood and not collecting enough blood in the tube, resulting in unusable samples. Many patients requiring a BC also have a peripheral intravenous catheter ("catheter") but these are not normally used for blood sampling. This means that patients receive many painful needles for both catheter insertion and blood sampling. There is a needle-free blood collection device (PIVO Pro) which can be used with a catheter to collect a blood sample. The goal of the PIVO Trial is to see if using the PIVO Pro for blood culture sample collection will have a lower amount of contamination than the usual method of blood sample collection. Patients 18 and older at 3 emergency departments will be included. Research nurses will look for patients in emergency who need a blood culture sample taken and they will be asked if they want to be involved in the trial. Half of the participants will use the PIVO Pro to take their blood sample and half will have the usual way of collecting blood. Participants do not have to do anything specifically for the trial. Information about the blood collection and results of the blood culture will be collected from the medical records and recorded for the trial.

Начало: 18.08.2025 Край: 31.12.2026 Възраст: от 18 г. Друго

Australia The University of Queensland NCT06806709

Набира участници Фаза 2

Open-label Extension Study in Participants With Early Alzheimer's Disease

Alzheimer's Disease

The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study. This study will assess the long-term safety and efficacy of GSK4527226 in participants with early AD (including mild cognitive impairment \[MCI\] and mild dementia due to AD) who have completed the parent study.

Начало: 14.08.2025 Край: 08.12.2028 Възраст: 50–85 г. Лечение

Argentina, Australia, Canada +8 GlaxoSmithKline NCT07105709

Набира участници Фаза 2

An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy

Focal Epilepsy

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.

Начало: 14.08.2025 Край: 01.06.2029 Възраст: 18–70 г. Лечение

Australia Shanghai Zhimeng Biopharma, Inc. NCT07238868

Набира участници Фаза 3

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Immune Thrombocytopenic Purpura (ITP)

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed. The main aim of this study is to check how safe mezagitamab is and how well it is tolerated by adults with chronic primary ITP, if given over a longer time. Other aims are to learn how effective treatment with mezagitamab is and how the body processes it (called pharmacokinetics or PK) over a longer time. Participants of the following previous mezagitamab studies will be invited to join this continuation study: TAK-079-3002 and TAK-079-1004. In this continuation study, participants will receive mezagitamab when certain protocol criteria are met. During the study, participants will visit their study clinic several times.

Начало: 14.08.2025 Край: 29.07.2029 Възраст: от 18 г. Лечение

Australia, Bulgaria, China +11 Takeda NCT06948318

Набира участници Фаза 2

FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

Aneurysmal Subarachnoid Hemorrhage

A multi-centre, prospective, blinded, randomised clinical trial of fludrocortisone compared with placebo in patients presenting with aneurysmal subarachnoid haemorrhage. The study aim is to determine if early administration of enteral fludrocortisone in aneurysmal subarachnoid haemorrhage reduce death and dependency at six months.

Начало: 13.08.2025 Край: 31.07.2030 Възраст: от 18 г. Лечение

Australia, New Zealand The George Institute NCT06409364

Набира участници Фаза 1

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

Advanced Solid Tumors

This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.

Начало: 12.08.2025 Край: 01.08.2030 Възраст: от 18 г. Лечение

Australia, India, United States Sun Pharma Advanced Research Company Limited NCT07042100

Набира участници Фаза 2

Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

COPD Acute Exacerbation

This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation

Начало: 12.08.2025 Край: 01.05.2026 Възраст: 40–80 г. Лечение

Argentina, Australia, Georgia +3 Connect Biopharm LLC NCT06940154

Набира участници Фаза 1/2

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Advanced Solid Tumor

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.

Начало: 12.08.2025 Край: 01.10.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Germany +4 BioNTech SE NCT07070232

Набира участници Фаза 2

Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes

Type 2 Diabetes Mellitus (T2DM) Food Effect Safety and Tolerability Obesity

The goal of this intervention study is to evaluate the safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of MKP10241 in obese participants with and without T2DM in 3 parts. The main parameters it aims to answers are : 1. Does food effects the pharmacokinetic parameters following a single dose of MKP10241 in healthy participants? 2. Will multiple ascending doses of MKP10241 in obese participants with or without T2DM characterize changes in the plasma pharmacokinetic profile and pharmacodynamic effects? 3. What treatment emergent adverse events or discontinuation is experienced following single and multiple ascending doses of MKP10241 in healthy and obese participants with or without T2DM? This study will be compared against a placebo which is matched in appearance to MKP10241 at dosage strengths. Participants will: 1. Part 1: Take MKP10241 400 mg or Placebo on Day 1 and Day 8. Part 2: Take MKP10241 200 mg, 300 mg and 400 mg or Placebo daily from Day 1 to Day 28 Part 3: Take MKP10241 300 mg and 400 mg or Placebo daily from Day 1 to Day 28 2. Visit the clinical research unit for dose administration, admission or follow up. 3. Will be monitored by the Safety Monitoring Committee.

Начало: 12.08.2025 Край: 17.04.2026 Възраст: 18–60 г. Лечение

Australia Mankind Pharma Limited NCT07098663

Набира участници Фаза 3

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.

Начало: 11.08.2025 Край: 01.03.2027 Възраст: от 18 г. Лечение

Australia, Canada, Germany +5 Novo Nordisk A/S NCT07076199

Набира участници Фаза 2

Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

Asthma Acute

This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation

Начало: 08.08.2025 Край: 01.05.2026 Възраст: 12–75 г. Лечение

Argentina, Australia, Georgia +3 Connect Biopharm LLC NCT06940141

Набира участници Фаза 2

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Alzheimer's Disease

This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.

Начало: 07.08.2025 Край: 31.12.2030 Възраст: 50–85 г. Лечение

Australia, Canada, Czechia +9 Novartis Pharmaceuticals NCT07094516

Набира участници Фаза 2

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.

Начало: 07.08.2025 Край: 06.04.2029 Възраст: от 18 г. Лечение

Australia, Canada, China +6 AstraZeneca NCT07098338

Набира участници Фаза 1

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Multiple doses of etentamig in combination with iberdomide will be explored. Each treatment arm receives a different dose of etentamig and iberdomide to determine a tolerable dose. Approximately 135 adult participants with R/R MM will be enrolled in the study in approximately 50 sites worldwide. In phase 1 participants will receive escalating intravenous (IV) etentamig in combination with oral iberdomide. In phase 2 participants will receive IV etentamig at one of two doses in combination with oral iberdomide, as part of the approximately 129 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and and monitoring of side effects.

Начало: 07.08.2025 Край: 01.03.2036 Възраст: от 18 г. Лечение

Australia, Canada, France +4 AbbVie NCT06896916

Набира участници

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

Post Partum Haemorrhage Maternal Care Patterns High Risk Pregnancy

Oli is a predictive, non-invasive device, intended to be placed on the participant's maternal abdomen during the intrapartum period, which can alert healthcare professionals of an impending cumulative blood loss of ≥500 ml (abnormal postpartum uterine bleeding) or cumulative blood loss of ≥1000ml (postpartum haemorrhage) at least 1 hour in advance of birth. This study is being undertaken to assess the performance of Oli measuring cumulative blood loss ≥500ml and ≥1000ml, as well as evaluate its safety profile.

Начало: 06.08.2025 Край: 30.07.2026 Възраст: от 18 г. Диагностика

Australia, United States Baymatob Operations Pty Ltd NCT06655207

Набира участници Фаза 1/2

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

Solid Tumors

This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.

Начало: 06.08.2025 Край: 02.12.2027 Възраст: от 18 г. Лечение

Australia, South Korea, United States ABL Bio, Inc. NCT07158918

Набира участници Фаза 2

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

Respiratory Syncytial Virus Infections

This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.

Начало: 06.08.2025 Край: 16.07.2027 Възраст: от 18 г. Превенция

Australia, Canada, Germany +5 GlaxoSmithKline NCT07092865

Набира участници Фаза 3

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Breast Cancer

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2-negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Advanced cancer is a term that is often used to describe cancer that is unlikely to be cured. Metastatic cancer is the type where the cancer cells spread from one part of the body to another. This study is seeking for participants whose breast cancer has gotten worsen after receiving cyclin dependent kinase (CDK) 4/6 inhibitor-based therapy. Half of participants in this study will receive their usual study treatment, everolimus with endocrine therapy (either exemestane or fulvestrant) for HR-positive/HER2-negative advanced or metastatic breast cancer (A/mBC). The study doctor will discuss which hormone therapy is right for the participant before treatment begins. PF-07248144 is a tablet that will be taken by mouth at home every day in a 28-day cycle. Fulvestrant will be given as two injections (one injection in the buttock) at visits to the study clinic. Everolimus and exemestane are also tablets and will be taken by mouth at home every day in a 28-day cycle. The study will compare the experiences of people receiving PF-07248144 in combination with fulvestrant to those of the people who do not. This will help see if PF-07248144 in combination with fulvestrant is safe and effective.

Начало: 05.08.2025 Край: 04.11.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +28 Pfizer NCT07062965

Набира участници Фаза 2

Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease

Celiac Disease

This study is a randomized, double-blind, placebo controlled clinical study to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FB102 in adult participants with well controlled (on a strict GFD) CeD following an oral gluten challenge.

Начало: 04.08.2025 Край: 28.02.2027 Възраст: 18–70 г. Лечение

Australia Forte Biosciences, Inc. NCT06982963

Набира участници Фаза 1

First-in-Human Trial of Oral AN2-502998

Healthy Volunteers

First-in-Human Phase 1, Single-Center, Randomized, Blinded, Placebo-Controlled Trial in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Oral AN2-502998

Начало: 04.08.2025 Край: 01.04.2026 Възраст: 18–55 г. Фундаментална наука

Australia AN2 Therapeutics, Inc NCT07024589

1 … 19 20 21 22 23 … 154